A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma

The Journal of Veterinary Medical Science
Elisabetta TreggiariSusan Margaret North

Abstract

A xenogeneic DNA vaccination has been licensed for use in dogs with locally controlled stage II and III oral malignant melanoma (OMM). At present, there are limited outcome data for dogs with OMM treated with surgery and immunotherapy. The aim of this study is to retrospectively review the outcome and survival of 32 dogs affected by OMM that were treated with a combination of surgery and the xenogeneic DNA vaccination (with the addition of radiotherapy in some cases) and to determine the influence of surgical margins and delay in receiving vaccination. The overall median survival time (MST) was 335 days (95% CI: 301-540 days), and the overall median progression-free survival (PFS) was 160 days (mean 182 days, 95% CI: 132-232 days). Stage, completeness of surgical margins and delay in administration of the vaccine did not appear to statistically influence survival or PFS, although these results may reflect the low statistical power of the study due to small numbers. Further studies are required to assess whether the addition of any adjuvant treatment to surgery, including immunotherapy, is able to significantly prolong survival in cases of canine oral melanoma.

References

Jan 1, 1979·Veterinary Pathology·D E Bostock
Nov 1, 1991·Veterinary Surgery : VS·J K KosovskyA K Patnaik
Sep 1, 1992·Veterinary Surgery : VS·J WallaceA K Patnaik
Jan 1, 1985·The American Journal of Dermatopathology·M H Goldschmidt
Sep 1, 1980·Veterinary Pathology·D E Bostock, M T Dye
Jul 1, 1994·Journal of Veterinary Internal Medicine·K E BatemanS A Kruth
May 10, 2001·Journal of the American Veterinary Medical Association·K M RassnickA S Moore
Jun 21, 2003·Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·David R ProulxDonald E Thrall
Feb 10, 2004·Journal of the American Veterinary Medical Association·Pedro A BoriaDeborah W Knapp
Apr 9, 2008·Journal of Immunotherapy·Henrik von EulerThomas H Tötterman
Aug 24, 2012·New Zealand Veterinary Journal·L K BrockleyP F Bennett
Jul 31, 2014·Journal of the American Veterinary Medical Association·Sarah E BostonPaolo Buracco

❮ Previous
Next ❯

Citations

Jan 18, 2017·The Journal of Small Animal Practice·S VergantiS Murphy
Jun 8, 2017·World Journal of Experimental Medicine·Liliana M E Finocchiaro, Gerardo C Glikin
Jun 22, 2019·Cancer Immunology, Immunotherapy : CII·Lidia TaroneFederica Riccardo
Apr 24, 2020·Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·Michelle TurekScott Hetzel
Aug 29, 2019·Veterinary and Comparative Oncology·Anais ProuteauBenoît Hédan
Apr 26, 2019·Scientific Reports·K L Bowlt BlacklockM Starkey
Mar 15, 2018·International Journal of Molecular Sciences·Giuseppina BarutelloFederica Riccardo
Feb 15, 2019·Veterinary Sciences·Ramón M Almela, Agustina Ansón
Mar 12, 2021·Advanced Drug Delivery Reviews·Lisa A Mestrinho, Ricardo R Santos

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

SPSS
Excel

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.